SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. (September 2020)

• Record Type: Journal Article
• Authors: Wei, Liqiang; Wang, Liang; Cong, Jia; Yang, Lei; Ye, Jin; Li, Xin; Yao, Na; Yang, Jing; Wang, Jingwen
• Is Part Of: Leukemia research. Volume 96(2020)
• Publication Date: 2020-09
• Subjects: Extranodal natural killer/T-cell lymphoma -- Nasal type -- Relapse -- Refractory -- Chemotherapy; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2020.106422
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: R/R-ENKTL is a relatively rare and fatal disease with no standard therapy. R/R-ENKTL patients had ORR and CR rates of 70.0 % and 45.0 % after SVILE treatment. Stage Ⅰ/Ⅱ and Ⅲ/Ⅳ patients had PFS and OS of 100.0 % vs. 26.7 % and 100.0 % vs. 40.0 %. The main adverse events were reversible haematological toxicity. SVILE regimen is a new therapeutic option for R/R-ENKTL patients. Abstract: Objective: To explore the effectiveness and safety of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide combination (SVILE regimen) in the treatment of relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (R/R-ENKTL). Methods: This descriptive, retrospective medical chart review assessed data from 20 R/R-ENKTL patients treated with the SVILE regimen between November 2014 and August 2019. Complete response (CR) rate, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) since SVILE treatment were analysed. Results: After receiving 1–5 SVILE regimen chemotherapy cycles (median 2 cycles), patients had ORR and CR rates of 70.0 % and 45.0 %, respectively. Stage Ⅰ/Ⅱ patients had CR rate of 100.0 % and stage Ⅲ/Ⅳ patients had ORR and CR rates of 60.0 % and 26.7 %, respectively. Three-year PFS and OS rates of the 20 patients were 43.8 % and 54.2 %, respectively. Three-year PFS and OS rates of stage Ⅰ/Ⅱ patients and stage Ⅲ/Ⅳ patients were 100.0 % vs. 26.7 % and 100.0 % vs. 40.0 % (P ＜ 0.05), respectively. The PFS and OS of patients who achieved CR after SVILE chemotherapy were significantly better than those of non-CR patients. The main adverse events were reversible haematological toxicity. Conclusions: The SVILE regimen is a new treatment option that is effective and safe for R/R-ENKTL patients.